# Pembrolizumab

## KEYTRUDA inj 100mg/4mL

| 藥物代碼 | IKEY1 |
| :--- | :--- |
| 適應症 | KEYTRUDA is a human programmed death receptor-1 \(PD-1\)-blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumaband, if BRAF V600 mutation positive, a BRAF inhibitor. |
| 副作用 | &gt;10%:Cardiovascular: Facial edema \(10%\)Central nervous system: Fatigue \(43%\)Dermatologic: Pruritus \(28%\), skin rash \(24%; immune-mediated: 1%\)Endocrine & metabolic: Hyperglycemia \(49%\), hypoalbuminemia \(37%\), hyponatremia \(37%\), hypertriglyceridemia \(33%\), decreased serum bicarbonate \(22%\), hypocalcemia \(21%\)Gastrointestinal: Constipation \(22%\), nausea \(22%\), decreased appetite \(20%\), diarrhea \(20%\), abdominal pain \(13%\), vomiting \(13%\)Hematologic & oncologic: Anemia \(44%; grades 3/4: 10%\), lymphocytopenia \(40%; grades 3/4: 9%\)Hepatic: Increased serum alkaline phosphatase \(26%\), increased serum AST \(24%\), increased serum ALT \(21%\)Neuromuscular & skeletal: Arthralgia \(14%\)Respiratory: Dyspnea \(?20%\), cough \(18%\)Miscellaneous: Fever \(14%\)1% to 10%:Central nervous system: Confusion \(&gt;2%\), peripheral neuropathy \(2%\)Endocrine & metabolic: Hypothyroidism \(immune-mediated; 9%\), hyperthyroidism \(immune-mediated; 3%\)Gastrointestinal: Colitis \(immune-mediated; 2%\)Immunologic: Antibody development \(2%\)Neuromuscular & skeletal: Weakness \(10%\), arthritis \(immune-mediated; 2%\)Respiratory: Pneumonitis \(3%\), pleural effusion \(&gt;2%\), pneumonia \(&gt;2%\), respiratory failure \(&gt;2%\) |
| 禁忌 | Hypersensitivity to pembrolizumab or any component of the formulation. |
| 藥物保存方式 | 2-8°C |
| 用法用量 | The recommended dose of KEYTRUDA is 2 mg/kg administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity. \[OFF-LABLE USE IN TAIWAN\] Colorectal cancer, Unresectable or metastatic, progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan - Microsatellite instability-high, Or mismatch repair deficient : 200 mg IV infusion over 30 minutes every 3 weeks; continue treatment for up to 24 months or until disease progression or unacceptable toxicity  Head and neck cancer, Recurrent or metastatic, squamous cell, with disease progression on or after platinum-based chemotherapy : 200 mg IV infusion over 30 minutes every 3 weeks; continue treatment for up to 24 months or until disease progression or unacceptable toxicity  Hodgkin's disease, Classical, refractory or relapsed after 3 or more prior lines of therapy : 200 mg IV infusion over 30 minutes every 3 weeks; continue treatment for up to 24 months or until disease progression or unacceptable toxicity Metastatic urothelial carcinoma, Or locally advanced, in patients not eligible for cisplatin-containing chemotherapy, or with progression during or after platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy : 200 mg IV infusion over 30 minutes every 3 weeks; continue treatment for up to 24 months or until disease progression or unacceptable toxicity  Microsatellite instability-high, Or mismatch repair deficient - Solid tumor, Unresectable or metastatic, progressed following prior treatment and who have no satisfactory alternative treatment options : 200 mg IV infusion over 30 minutes every 3 weeks; continue treatment for up to 24 months or until disease progression or unacceptable toxicity Non-small cell lung cancer, Metastatic, high PD-L1 expression, first-line treatment, with no EGFR or ALK tumor aberrations : 200 mg IV infusion over 30 minutes every 3 weeks; continue treatment for up to 24 months or until disease progression or unacceptable toxicity  Non-small cell lung cancer, Metastatic, PD-L1 expression, with disease progression on or after platinum-based chemotherapy; patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving pembrolizumab : 200 mg IV infusion over 30 minutes every 3 weeks; continue treatment for up to 24 months or until disease progression or unacceptable toxicity  Nonsquamous non-small cell lung cancer, Metastatic, first-line treatment in combination with pemetrexed and carboplatin : 200 mg IV infusion over 30 minutes every 3 weeks, for up to 24 months or until disease progression or unacceptable toxicity. Give prior to pemetrexed 500 mg/m\(2\) IV and carboplatin AUC 5 mg/mL/min IV on day 1 of each 21-day cycle for 4 cycles, followed by pembrolizumab monotherapy with or without pemetrexed maintenance. |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 尚未確立 |
| 孕期用藥建議 | Contraindicated |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Potential Toxicity\(Mother\) 無\(很少\)資料 - 避免使用\(母體\) |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | IVD |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | 【D5W】 可選  【N/S】 可選 |
| IVP 用法建議 | N/A |
| IVD 用法建議 | IV infusion over 30 minutes. |
| 注意事項 | 製備: 1. 抽取需要的藥量，注入0.9%氯化鈉注射液或5%葡萄糖注射液的靜脈輸注袋中。\(輕轉的方式混勻溶液\)。 2. 溶液的最終濃度應為1毫克/毫升至10毫克/毫升之間。 6. 稀釋後可存放室溫，但不可超過6小時。\(包括於室溫下，泡製後之藥瓶的存放時間、IV袋中之輸注溶液的存放時間、以及輸注所需要的時間\) |

